CN118829428A - 治疗人类癌症的口服pclx-001 - Google Patents

治疗人类癌症的口服pclx-001 Download PDF

Info

Publication number
CN118829428A
CN118829428A CN202380025222.6A CN202380025222A CN118829428A CN 118829428 A CN118829428 A CN 118829428A CN 202380025222 A CN202380025222 A CN 202380025222A CN 118829428 A CN118829428 A CN 118829428A
Authority
CN
China
Prior art keywords
pclx
cancer
hours
per day
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380025222.6A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·罗伯特·麦基
尼尔·梅纳德·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacylex Pharmaceuticals Inc
Original Assignee
Pacylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc filed Critical Pacylex Pharmaceuticals Inc
Publication of CN118829428A publication Critical patent/CN118829428A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380025222.6A 2022-03-03 2023-03-03 治疗人类癌症的口服pclx-001 Pending CN118829428A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
US63/316,153 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (1)

Publication Number Publication Date
CN118829428A true CN118829428A (zh) 2024-10-22

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380025222.6A Pending CN118829428A (zh) 2022-03-03 2023-03-03 治疗人类癌症的口服pclx-001

Country Status (10)

Country Link
US (1) US20250161299A1 (https=)
EP (1) EP4486344A4 (https=)
JP (1) JP2025507923A (https=)
KR (1) KR20240155234A (https=)
CN (1) CN118829428A (https=)
AU (1) AU2023228703A1 (https=)
CA (1) CA3244234A1 (https=)
IL (1) IL314984A (https=)
MX (1) MX2024010584A (https=)
WO (1) WO2023164776A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Also Published As

Publication number Publication date
JP2025507923A (ja) 2025-03-21
WO2023164776A1 (en) 2023-09-07
MX2024010584A (es) 2024-09-06
KR20240155234A (ko) 2024-10-28
AU2023228703A1 (en) 2024-09-12
CA3244234A1 (en) 2023-09-07
EP4486344A4 (en) 2026-03-04
IL314984A (en) 2024-10-01
EP4486344A1 (en) 2025-01-08
US20250161299A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
Jin et al. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
CN112566660B (zh) 具有braf突变的癌症的组合疗法
Zheng et al. Tyrosine threonine kinase inhibition eliminates lung cancers by augmenting apoptosis and polyploidy
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN118829428A (zh) 治疗人类癌症的口服pclx-001
EP3405203A1 (en) Methods for treating cancer
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
CN103582479A (zh) 用pi3k抑制剂化合物治疗间皮瘤的方法
US20200405719A1 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
CN111358952B (zh) 一种抗肿瘤药物组合物及其制剂和应用
JP5274458B2 (ja) 黒色腫における治療応答のための早期指標としての黒色腫阻害性活性（ｍｉａ）タンパク質の使用
US20240261289A1 (en) Sotorasib dosing regimen
KR20140011311A (ko) Ｐｉ３ｋ 억제제 및 ｍｅｋ 억제제를 포함하는 조성물 및 암을 치료하기 위한 이의 용도
WO2025050208A1 (en) Oral pclx-001 in the treatment of human cancer
Bhargava et al. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer
JP7671465B2 (ja) 末梢血循環腫瘍細胞の解析を用いたがんの治療方法
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
TW202434251A (zh) 治療癌症之療法
WO2026019787A1 (en) Methods of treating merkel cell carcinoma with tryptophan hydroxylase inhibitors
AU2024380949A1 (en) Alectinib for the treatment of alk fusion-positive solid or cns tumours
TW202245785A (zh) 兒童癌症治療用之醫藥組成物
CN120093845A (zh) 一种中药组合物在制备治疗肝癌药物中的应用
JP2022533567A (ja) 没食子酸エピガロカテキンとチロシンキナーゼ阻害剤との併用の、癌治療薬の製造への用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination